Last reviewed 2026-04-22 · How we verify

Cefdinir (drug)

Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Community-acquired pneumonia, Acute exacerbation of chronic bronchitis, Acute bacterial otitis media.

At a glance

Mechanism of action

Cefdinir works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against common respiratory and urinary tract pathogens. The drug is bactericidal and is commonly used for community-acquired infections.

Approved indications

• Community-acquired pneumonia
• Acute exacerbation of chronic bronchitis
• Acute bacterial otitis media
• Pharyngitis/tonsillitis
• Uncomplicated urinary tract infection
• Skin and soft tissue infections

Common side effects

• Diarrhea
• Nausea
• Headache
• Vaginal yeast infection
• Abdominal pain
• Rash

Key clinical trials

• Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
• Cefdinir Capsules 300 mg, Fasting (PHASE1)
• Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting (PHASE1)
• Cefdinir for Oral Suspension 250 mg/5mL, Fasting (PHASE1)
• Cefdinir Capsules 300 mg, Non-fasting (PHASE1)
• Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting (PHASE2)
• Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.